Teva launches another MS trial for laquinimod; MultiVir sets out for $60M IPO;

@FierceBiotech: AstraZeneca loans its oncology star to Celgene, recruits Innate in a PD-L1 deal spree. News | Follow @FierceBiotech

@JohnCFierce: Aerie shares crushed after glaucoma therapy flops in PhIII. Story | Follow @JohnCFierce

> Teva ($TEVA) and partner Active Biotech kicked off a Phase II study of their laquinimod in a Phase II study in primary progressive multiple sclerosis. More

> The FDA granted a priority review for AbbVie's ($ABBV) cocktail treatment for genotype 4 hepatitis C. Item

> Gene therapy biotech MultiVir set terms for a $60 million IPO. Story

Medical Device News

@FierceMedDev: Low-cost smart syringe shoots for reduced disease transmission. News | Follow @FierceMedDev

@VarunSaxena2: Ahead of Apple Watch launch, hearing aid company reveals its app development experience. Story | Follow @VarunSaxena2

@EmilyWFierce: Medical device makers such as $GE, $ABT, $BSX and $JNJ forming the first industry trade group in #Asia. Pharmalot story | Follow @EmilyWFierce

> Bard's Lutonix drug-coated balloons help lift Q1 earnings. News

> FDA deems all 4,000+ of troubled Maquet's left atrial appendage closure devices potentially deadly, announces major recall. More

Pharma News

@FiercePharma: Labeling foul-up involving acetaminophen leads RB to recall 135 lots of Mucinex. News | Follow @FiercePharma

@EricPFierce: Bayer to close a vet med plant in Missouri it bought from Teva. 130 workers to lose jobs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10. Story | Follow @CarlyHFierce

> BMS scores positive EMA opinion for Opdivo in advanced melanoma patients. More

> AstraZeneca sales retreat in its effort to achieve huge growth by 2023. News

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.